New radiation drug targets Hard-to-Treat prostate cancer in first human trial
NCT ID NCT06217822
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug delivers radiation directly to cancer cells to damage them. The main goals are to check safety, find the best dose, and see if tumors shrink. About 198 participants will receive the drug as an injection every 6 to 8 weeks for up to 4 cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AZ Groeninge Campus Kennedylaan - Urology
RECRUITINGKortrijk, 8500, Belgium
-
Akademiska sjukhuset i Uppsala - Fas 1-enheten
SUSPENDEDUppsala, Uppsala County, 751 85, Sweden
-
BC Cancer | Vancouver
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
-
Centre Hospitalier de l'Universite de Montreal (CHUM) | Oncology
RECRUITINGMontreal, Quebec, H2X 0C1, Canada
-
Centre hospitalier universitaire de Sherbrooke (CHUS) | Oncology
RECRUITINGSherbrooke, Quebec, J1H 5N4, Canada
-
City of Hope - Duarte Cancer Center
NOT_YET_RECRUITINGDuarte, California, 91010, United States
-
Cross Cancer Institute | Clinical Trials Unit
WITHDRAWNEdmonton, Alberta, T6G 1Z2, Canada
-
Docrates Mehiläinen Syöpäsairaala
NOT_YET_RECRUITINGHelsinki, Uusimaa, 00180, Finland
-
Erasmus Medisch Centrum
WITHDRAWNRotterdam, South Holland, 3015 CE, Netherlands
-
HUS-Yhtymä, Helsingin yliopistollinen sairaala (HUS) - Syöpäkeskus
RECRUITINGHelsinki, Uusimaa, 00029, Finland
-
IRCCS Istituto Nazionale Tumori Fondazione Pascale - S. C. Medicina Nucleare e Terapia Metabolica
NOT_YET_RECRUITINGNaples, 80131, Italy
-
Institut Jules Bordet / Nuclear Medicine
RECRUITINGAnderlecht, 1070, Belgium
-
Istituto Europeo di Oncologia s.r.l - Medicina Nucleare
RECRUITINGMilan, 20141, Italy
-
Juravinski Cancer Centre | Clinical Trials
RECRUITINGHamilton, Ontario, L8V 5C2, Canada
-
Kantonsspital Baden
WITHDRAWNBaden, Canton of Aargau, 5404, Switzerland
-
Karolinska Universitetssjukhuset - Fas I-enheten Solna CKC
RECRUITINGStockholm, Stockholm County, 171 76, Sweden
-
Kuopio University Hospital, Kuopion yliopistollinen sairaala (KYS) - Syövänhoitokeskus
RECRUITINGKuopio, Northern Savonia, 70210, Finland
-
M Health Fairview Masonic Cancer Clinic - Clinics and Surgery Center
NOT_YET_RECRUITINGMinneapolis, Minnesota, 55455, United States
-
McGill University Health Centre (MUHC) - Research Institute (RI) - McConnell Centre for Innovative Medicine (CIM)
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
-
Princess Margaret Cancer Centre - University Health Network - Department of Medical Oncology and Hematology
RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
Sahlgrenska Universitetssjukhuset - Klinisk prövningsenhet Fas I/FIH
RECRUITINGGothenburg, Västra Götaland County, 413 46, Sweden
-
Skånes Universitetssjukhus Lund - Onkologens kliniska forskningsenhet
RECRUITINGLund, Skåne County, 221 85, Sweden
-
Tampere University Hospital, Tampereen yliopistollinen sairaala (TAYS) - Syöpäkeskus
SUSPENDEDTampere, Pirkanmaa, 33520, Finland
-
The Cancer Institute Hospital of JFCR
NOT_YET_RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
-
The Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital - Cancer Trials Research Centre
NOT_YET_RECRUITINGNewcastle upon Tyne, Tyne and Wear, NE7 7DN, United Kingdom
-
The Royal Marsden NHS Foundation Trust | Sutton - Oak Foundation Drug Development Unit
ACTIVE_NOT_RECRUITINGSutton, Surrey, SM2 5PT, United Kingdom
-
The University of Texas MD Anderson Cancer Center - Texas Medical Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Turku University Hospital, Turun yliopistollinen sairaala (TYKS) - Syöpäkeskus
RECRUITINGTurku, Southwest Finland, 20540, Finland
-
UZ Leuven - Campus Gasthuisberg - Nuclear Medicine
NOT_YET_RECRUITINGLeuven, 3000, Belgium
-
Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
RECRUITINGGroningen, 9713 GZ, Netherlands
-
University College London Hospitals NHS Foundation Trust | University College Hospital - NIHR UCLH Clinical Research Facility
RECRUITINGLondon, Greater London, W1T 7HA, United Kingdom
-
Universitätsspital Basel
NOT_YET_RECRUITINGBasel, Canton of Basel-City, 4056, Switzerland
-
Univestitätsspital Zürich (USZ)
RECRUITINGZurich, 8091, Switzerland
-
XCancer Omaha
NOT_YET_RECRUITINGOmaha, Nebraska, 68130, United States
-
Yokohama City University Hospital
NOT_YET_RECRUITINGYokohama, Kanagawa, 236-0004, Japan
Conditions
Explore the condition pages connected to this study.